Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The L-Lysyl-D-alanyl-D-alanine (Lys-D-Ala-D-Ala) terminus is a critical structural component of the peptidoglycan precursor, specifically found in the cell walls of many Gram-positive bacteria (StatPearls, NBK459363). It serves as the substrate for penicillin-binding proteins (PBPs), which catalyze the cross-linking of peptidoglycan chains to provide mechanical strength to the bacterial cell wall (Nature Reviews Microbiology, 2017). This terminus is the primary molecular target for glycopeptide antibiotics, such as vancomycin and teicoplanin. These drugs bind to the D-Ala-D-Ala dipeptide with high affinity, physically blocking the enzymes responsible for cell wall assembly (PubMed, 29075017). Disruption of this process leads to weakened cell walls and eventual osmotic lysis of the bacteria. Resistance to these antibiotics often involves the modification of this target to D-Ala-D-Lac or D-Ala-D-Ser, which significantly reduces drug binding affinity (NIH, PMC4522021). This target is unique to bacteria, providing a high degree of selective toxicity for antimicrobial therapy.
Glycopeptide antibiotics bind to the D-Ala-D-Ala terminus of the peptidoglycan precursor through five hydrogen bonds. This binding sterically inhibits the transglycosylation and transpeptidation steps of cell wall synthesis, preventing the cross-linking of the peptidoglycan layer and leading to bacterial cell lysis (StatPearls, NBK459363; Nature Reviews Microbiology, 2017).
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on L-Lysyl-D-alanyl-D-alanine terminus of peptidoglycan precursor (Lys-D-Ala-D-Ala).